Market Research2024-02-19T15:55:31+00:00

Loading...

Turning Analysis in to Actionable Insights

Your team needs information in order to make the best decisions to ensure access to your product(s). By combining our understanding of the marketplace, relationships with key stakeholders, and expertise in market research methodologies, Innovation Partners Market Research and Data Analytics services can help you to turn analysis in to actionable insights.

At Innovation Partners, we seek to be a resource to our clients and partners. As you explore our service offerings, be sure to check out our Key Insights from our team of experts.

Build a Custom Strategy

Access the IP Illuminator, our proprietary strategy building tool, to build a customized plan of strategic solutions IP can offer to meet your unique needs.

Understanding Market Potential

Innovation Partners will employ various methods to conduct a thorough evaluation of the competitive landscape for your product(s). Utilizing commercial and Medicare claims data, one-on-one interviews, advisory boards, clinical trial data review, literature review, conference coverage, and other strategies we will analyze data to understand the current and future competitive market in support of product positioning, pricing, and estimated sales forecasting models to support and enhance value discussions with provider, payer and other stakeholders. Insights include:

  • Analysis of competitive contracts
  • Patient Journey Analysis
  • Sales Forecasting
  • Price Sensitivity Analysis

Innovation Partners will utilize a combination of qualitative and quantitative methods to understand the needs of diverse segments within each stakeholder audience.  Attitudes, behaviors, emotions Qualitative research will be used to develop hypothesis about potential segments and areas of differentiation which will be explored in quantitative research. Analysis will provide several potential segmentation approaches that will be finalized with client team.

The TPP which communicates potential scenarios (best-worst case efficacy, AEs) or actual as seen in later clinical trial results informs many of the decisions and tactics that are needed by commercial teams:

These include Early Phase Research with potential TPP scenarios can also be used n early phases to inform the strategy for pipeline innovations and assess those with more favorable forecasts.

Business Development/Licensing of external assets where the TPP is used to assess interest in the product, potential use and an early estimate of market size.

PreLaunch activities to help the Commercial team refine their and strategic plan for the product.
In order to optimize your KOL Identification and Outreach plan, our team will develop a map of potential influencers across Academic Hospitals and Large Community Oncology Practices with the potential to act as champions for your product in support of increased access for patients through a quantitative peer-nomination process.

To support your overall pricing and reimbursement strategy, our team leverages various research methods, including use of epidemiology studies, real-world evidence (RWE), and health-economics outcomes research, to develop budget impact models in support of a financial impact assessment for your product. Insights include:

  • Per Member Per Month (PMPM) impact modeling
  • Affordability Research and Analysis
  • Pricing Research and Analysis
  • Price and Reimbursement (P&R) dossier, Health Technology Assessment (HTA) dossier, and/or global value dossier optimization

Access to KOLs and other key stakeholders for meetings and research, assess your competitors’ booths/attendance; attend competitor presentations to understand their positioning vs. your product.

Research to help you and your team optimize the planned distribution partners and contract offers. Utilize qualitative market research to understand how the market place views potential plans. Identify the barriers, particularly as they pertain to large oncology practices.

Access & Reimbursement Solutions

Innovation Partners drives your commercial success and value proposition strategy through in-depth qualitative and quantitative market research, one-on-one interviews, advisory boards, as well as literature review, HEOR studies, and clinical trial data. Innovation Partners supports your product development strategy and provides the insights needed to design the robust value story to meet the needs of your future clients. Through primary and secondary research and advisory boards, you will reach stakeholders across the oncology ecosystem to determine the best strategy to position your product and showcase unmet need.

Innovation Partners will conduct primary market research to evaluate the current awareness profile of a specific disease state, diagnosis, and treatment options among health care professionals, in order to identify gaps and needs relative to provider education and awareness. Research will provide insights relative to practice setting, geography and specialty for benchmarking.

Through one-on-one interviews or advisory boards with key decision makers, Innovation Partners will provide insight into the current public and private payer landscape for a specific therapeutic class. By leveraging our relationships with National and Regional Health Plans, Integrated Delivery Networks (IDNs), Pharmacy Benefit Managers (PBMs), Group Purchasing Organizations (GPOs), Specialty Pharmacies (SPs) and Medicare Administrative Contractor (MAC) jurisdictions, we support product and/or disease-state specific research and will pressure test your pricing, reimbursement and contracting strategy in consideration of sites of care in the community, hospital outpatient and academic settings.

In order to develop a Clinical Pathways Strategy, your team needs to first understand the current landscape as it relates to therapeutic class. Innovation Partners’ Landscape Mapping provides insights into how various payer organizations are managing oncology, hematology and/or rare disease treatment options through clinical pathway relationships. Strategic research will illuminate how clinical pathways and payer agreements are impacting product access at the provider level, ultimately driving market share and product utilization/access down to the point of care. 12

12. Key Insight: Large oncology/hematology practice networks will often develop home-grown pathways in addition to using several payer-directed pathways. Innovation Partners can help you to navigate the complexities of these arrangements and understand how they are impacting provider decision making at the point of care.

Through engagement of key decision-makers you will be able to understand the key steps in the process, key metrics and how the data for metrics is sourced.

In support of your companies’ Group Purchasing Organization (GPO) and Specialty Distribution Contracting Strategy, IP will employ primary market research with key stakeholders to evaluate the market landscape and to gain an understanding of competitive contracting strategies and policies in place across key competitors. The research will seek to understand how your product’s competitive market basket is being managed across community oncology practices and within hospital outpatient sites of care, in consideration of factors driving contract design, execution and contract efficient, rebates, tiering, discounts, contract length, exit parameters, market share and volume based parameters, portfolio bundling, etc.

IP will develop a comprehensive clinical compendium overview across the five major clinical compendia organizations recognized for coverage determination within oncology/hematology, for the management of competitive products within a specific disease state in order to inform your company’s clinical compendium strategy.

The overview will aim to identify if competitive products are being managed within a specific disease area, across clinical compendia. Where the disease is being managed, the overview will contain an in-depth review of each clinical compendium reference organization, including but not limited to the competitive market basket, required levels of evidence, submission process, clinical, economic, and other submission criteria in scope for each submission.

IP will support your market access team to gain a baseline understanding of EMR system visibility for your product across priority hospitals and community practices, in order to understand patient access at the point of care. A combination of qualitative and quantitative research methodologies will assess and monitor the placement of your product within major oncology/hematology EMR systems, in order to identify opportunities and barriers to patient access, and monitor changes over time.

Obtain real world research on your product to ensure there are few restrictions in access. Research will inform your team about how the range of national and regional payers will approach your product as well as the challenges it will face.

Identifying Stakeholders and Testing Messaging and Communications

Many stakeholders play a role in ensuring access for patients; providers in the community and academic settings, leaders at infusion clinics, decision-makers within IDNs, health plans, trade and distribution, officials from regulatory/HTA agencies, professional societies, compendia organizations, and advocacy organizations. In order to optimize your KOL Identification and Outreach plan, our team will develop a map of potential influencers across Academic Hospitals and Large Community Oncology Practices with the potential to act as champions for your product in support of increased access for patients.

As a first step, our expert team will conduct secondary research to understand provider reach, including completion of a medical literature review to identify influential publishers and a review of CME events/major conferences to identify influential speakers/presenters with expertise and influence in disease and who have the capacity to impact access, coverage, and reimbursement for the product in support of increased access for patients through a quantitative peer-nomination process.

Following the secondary research, identified HCPs will be validated through primary market research quantitative interviews to execute the peer-nomination process to identify key influencers and opinion leaders in the disease, specifically as it relates to access for your product.

Innovation Partners’ deep expertise in oncology, hematology, and rare diseases guides the creation of a custom and comprehensive map of individuals and organizations who have the capacity to impact access, coverage, and reimbursement for your portfolio. Whether you are bringing your first product to market or entering a new therapeutic area, our team will leverage our deep relationships with influencers to identify the key decision-makers you need to engage to ensure future success.

Validate the appeal and relevance of potential positioning platforms for your product among oncology/hematology providers, in consideration of unmet needs, differentiation, and key benefits.

Innovation Partners drives your commercial success and value proposition strategy through in-depth qualitative and quantitative market research, one-on-one interviews, advisory boards, as well as literature review, HEOR studies, and clinical trial data. Innovation Partners supports your product development strategy and provides the insights needed to design the robust value story to meet the needs of your future clients. Through primary and secondary research and advisory boards, you will reach stakeholders across the oncology ecosystem to determine the best strategy to position your product and showcase unmet need.

Using qualitative/quantitative methods to determine which concept(s) will align with the positioning and gain marketplace attention.

Test discrete messaging as it appears in specific marketing materials, specifically in consideration of MOA, Efficacy, Safety, and other key attributes of your product. Provide recommendations to refine and optimize the materials in consideration of your Corporate goals and objectives.

Launch Solutions

Using quantitative survey methodologies, Innovation Partners will evaluate the efficiency and effectiveness of your virtual and in-person field-based engagements. IP’s dedicated market research experts will work with you to develop key questions, identify and survey respondents, and provide real-time feedback through quantitative benchmarking and analysis. With access to thousands of providers, our team will deploy surveys to your preferred network, whether it be 10 or 100 contacts, and provide rapid results. Quarterly reports will provide geographic breakdowns designed to highlight national and regional trends and address any barriers to access.

The TPP which communicates potential scenarios (best-worst case efficacy, AEs) or actual as seen in later clinical trial results informs many of the decisions and tactics that are needed by commercial teams: These include Early Phase Research with potential TPP scenarios can also be used n early phases to inform the strategy for pipeline innovations and assess those with more favorable forecasts. Business Development/Licensing of external assets where the TPP is used to assess interest in the product, potential use and an early estimate of market size. PreLaunch activities to help the Commercial team refine their and strategic plan for the product.

In order to optimize your KOL Identification and Outreach plan, our team will develop a map of potential influencers across Academic Hospitals and Large Community Oncology Practices with the potential to act as champions for your product in support of increased access for patients through a quantitative peer-nomination process.

As a first step, our expert team will conduct secondary research to understand provider reach, including completion of a medical literature review to identify influential publishers and a review of CME events/major conferences to identify influential speakers/presenters with expertise and influence in disease and who have the capacity to impact access, coverage, and reimbursement for the product in support of increased access for patients through a quantitative peer-nomination process.

Following the secondary research, identified HCPs will be validated through primary market research quantitative interviews to execute the peer-nomination process to identify key influencers and opinion leaders in the disease, specifically as it relates to access for your product.

Access to KOLs and other key stakeholders for meetings and research, assess your competitors’ booths/attendance; attend competitor presentations to understand their positioning vs. your product.

IP will conduct primary market research aimed at understanding the level of market awareness, source of awareness, familiarity, and perceptions of your company vs. key competitors and product vs. key competitors. Baseline assessments are conducted in advance of FDA approval in order to allow for the tracking of trends over time and market performance updates will allow your company to see the impact of your commercialization efforts. ATU research will also aim to understand the awareness and recall of your product’s clinical research findings, how clinicians react to them and why; how clinicians learn of about your product’s clinical findings, opportunities and barriers for your product, and the level of competitor activity in the market (e.g.; sales rep calls, MSLs).

Voice of the customer research will inform what messages stakeholders are retaining and how they are informing and impacting consideration of your product.

Often packaging/labeling/IFU are not vetted for use by the target stakeholders and become a problem to solve. Ensuring that stakeholders are able to efficiently and accurately use the product proactively informs the final materials.

Your materials shouldn’t raise more questions than answers. Conduct research with stakeholders to ensure the time, effort and budget investments are yielding materials that will inform and educate clearly and effectively.

Voice of the customer research will inform what messages stakeholders are retaining and how they are informing and impacting consideration of your product.

Business Development Due Diligence

As you look to license or acquire new assets, having a trusted partner to provide reliable information and guide you in your decisions is essential. Innovation Partners has the experience and expertise to analyze market potential, develop sales forecasting and price sensitivity analyses, and present a comprehensive outlook on the market access landscape in order to support recommendations for your business development teams. Our relationships with experts across oncology, hematology, and rare disease combined with our team’s experience working within early stage, mid-size, and multi-national manufacturers can give you the peace of mind to ensure your decisions are well-informed, setting you up for long-term success.

The TPP which communicates potential scenarios (best-worst case efficacy, AEs) or actual as seen in later clinical trial results informs many of the decisions and tactics that are needed by commercial teams: These include Early Phase Research with potential TPP scenarios can also be used n early phases to inform the strategy for pipeline innovations and assess those with more favorable forecasts. Business Development/Licensing of external assets where the TPP is used to assess interest in the product, potential use and an early estimate of market size. PreLaunch activities to help the Commercial team refine their and strategic plan for the product.

Roster & Brand Experience

To see our client roster and brand experience contact us for a copy of our capabilities presentation.


Loading...

Turning analysis in to actionable insights

Your team needs information in order to make the best decisions to ensure access to your product(s). By combining our understanding of the marketplace, relationships with key stakeholders, and expertise in market research methodologies, Innovation Partners Market Research and Data Analytics services can help you to turn analysis in to actionable insights.

At Innovation Partners, we seek to be a resource to our clients and partners. As you explore our service offerings, be sure to check out our Key Insights from our team of experts.

Build a Custom Strategy

Access the IP Illuminator, our proprietary strategy building tool, to build a customized plan of strategic solutions IP can offer to meet your unique needs.

Understanding Market Potential

Innovation Partners will employ various methods to conduct a thorough evaluation of the competitive landscape for your product(s). Utilizing commercial and Medicare claims data, one-on-one interviews, advisory boards, clinical trial data review, literature review, conference coverage, and other strategies we will analyze data to understand the current and future competitive market in support of product positioning, pricing, and estimated sales forecasting models to support and enhance value discussions with provider, payer and other stakeholders. Insights include:

  • Analysis of competitive contracts
  • Patient Journey Analysis
  • Sales Forecasting
  • Price Sensitivity Analysis

Innovation Partners will utilize a combination of qualitative and quantitative methods to understand the needs of diverse segments within each stakeholder audience.  Attitudes, behaviors, emotions Qualitative research will be used to develop hypothesis about potential segments and areas of differentiation which will be explored in quantitative research. Analysis will provide several potential segmentation approaches that will be finalized with client team.

The TPP which communicates potential scenarios (best-worst case efficacy, AEs) or actual as seen in later clinical trial results informs many of the decisions and tactics that are needed by commercial teams:

These include Early Phase Research with potential TPP scenarios can also be used n early phases to inform the strategy for pipeline innovations and assess those with more favorable forecasts.

Business Development/Licensing of external assets where the TPP is used to assess interest in the product, potential use and an early estimate of market size.

PreLaunch activities to help the Commercial team refine their and strategic plan for the product.
In order to optimize your KOL Identification and Outreach plan, our team will develop a map of potential influencers across Academic Hospitals and Large Community Oncology Practices with the potential to act as champions for your product in support of increased access for patients through a quantitative peer-nomination process.

To support your overall pricing and reimbursement strategy, our team leverages various research methods, including use of epidemiology studies, real-world evidence (RWE), and health-economics outcomes research, to develop budget impact models in support of a financial impact assessment for your product. Insights include:

  • Per Member Per Month (PMPM) impact modeling
  • Affordability Research and Analysis
  • Pricing Research and Analysis
  • Price and Reimbursement (P&R) dossier, Health Technology Assessment (HTA) dossier, and/or global value dossier optimization

Access to KOLs and other key stakeholders for meetings and research, assess your competitors’ booths/attendance; attend competitor presentations to understand their positioning vs. your product.

Research to help you and your team optimize the planned distribution partners and contract offers. Utilize qualitative market research to understand how the market place views potential plans. Identify the barriers, particularly as they pertain to large oncology practices.

Access & Reimbursement Solutions

Innovation Partners drives your commercial success and value proposition strategy through in-depth qualitative and quantitative market research, one-on-one interviews, advisory boards, as well as literature review, HEOR studies, and clinical trial data. Innovation Partners supports your product development strategy and provides the insights needed to design the robust value story to meet the needs of your future clients. Through primary and secondary research and advisory boards, you will reach stakeholders across the oncology ecosystem to determine the best strategy to position your product and showcase unmet need.

Innovation Partners will conduct primary market research to evaluate the current awareness profile of a specific disease state, diagnosis, and treatment options among health care professionals, in order to identify gaps and needs relative to provider education and awareness. Research will provide insights relative to practice setting, geography and specialty for benchmarking.

Through one-on-one interviews or advisory boards with key decision makers, Innovation Partners will provide insight into the current public and private payer landscape for a specific therapeutic class. By leveraging our relationships with National and Regional Health Plans, Integrated Delivery Networks (IDNs), Pharmacy Benefit Managers (PBMs), Group Purchasing Organizations (GPOs), Specialty Pharmacies (SPs) and Medicare Administrative Contractor (MAC) jurisdictions, we support product and/or disease-state specific research and will pressure test your pricing, reimbursement and contracting strategy in consideration of sites of care in the community, hospital outpatient and academic settings.

In order to develop a Clinical Pathways Strategy, your team needs to first understand the current landscape as it relates to therapeutic class. Innovation Partners’ Landscape Mapping provides insights into how various payer organizations are managing oncology, hematology and/or rare disease treatment options through clinical pathway relationships. Strategic research will illuminate how clinical pathways and payer agreements are impacting product access at the provider level, ultimately driving market share and product utilization/access down to the point of care. 12

12. Key Insight: Large oncology/hematology practice networks will often develop home-grown pathways in addition to using several payer-directed pathways. Innovation Partners can help you to navigate the complexities of these arrangements and understand how they are impacting provider decision making at the point of care.

Through engagement of key decision-makers you will be able to understand the key steps in the process, key metrics and how the data for metrics is sourced.

In support of your companies’ Group Purchasing Organization (GPO) and Specialty Distribution Contracting Strategy, IP will employ primary market research with key stakeholders to evaluate the market landscape and to gain an understanding of competitive contracting strategies and policies in place across key competitors. The research will seek to understand how your product’s competitive market basket is being managed across community oncology practices and within hospital outpatient sites of care, in consideration of factors driving contract design, execution and contract efficient, rebates, tiering, discounts, contract length, exit parameters, market share and volume based parameters, portfolio bundling, etc.

IP will develop a comprehensive clinical compendium overview across the five major clinical compendia organizations recognized for coverage determination within oncology/hematology, for the management of competitive products within a specific disease state in order to inform your company’s clinical compendium strategy.

The overview will aim to identify if competitive products are being managed within a specific disease area, across clinical compendia. Where the disease is being managed, the overview will contain an in-depth review of each clinical compendium reference organization, including but not limited to the competitive market basket, required levels of evidence, submission process, clinical, economic, and other submission criteria in scope for each submission.

IP will support your market access team to gain a baseline understanding of EMR system visibility for your product across priority hospitals and community practices, in order to understand patient access at the point of care. A combination of qualitative and quantitative research methodologies will assess and monitor the placement of your product within major oncology/hematology EMR systems, in order to identify opportunities and barriers to patient access, and monitor changes over time.

Obtain real world research on your product to ensure there are few restrictions in access. Research will inform your team about how the range of national and regional payers will approach your product as well as the challenges it will face.

Identifying Stakeholders and Testing Messaging and Communications

Many stakeholders play a role in ensuring access for patients; providers in the community and academic settings, leaders at infusion clinics, decision-makers within IDNs, health plans, trade and distribution, officials from regulatory/HTA agencies, professional societies, compendia organizations, and advocacy organizations. In order to optimize your KOL Identification and Outreach plan, our team will develop a map of potential influencers across Academic Hospitals and Large Community Oncology Practices with the potential to act as champions for your product in support of increased access for patients.

As a first step, our expert team will conduct secondary research to understand provider reach, including completion of a medical literature review to identify influential publishers and a review of CME events/major conferences to identify influential speakers/presenters with expertise and influence in disease and who have the capacity to impact access, coverage, and reimbursement for the product in support of increased access for patients through a quantitative peer-nomination process.

Following the secondary research, identified HCPs will be validated through primary market research quantitative interviews to execute the peer-nomination process to identify key influencers and opinion leaders in the disease, specifically as it relates to access for your product.

Innovation Partners’ deep expertise in oncology, hematology, and rare diseases guides the creation of a custom and comprehensive map of individuals and organizations who have the capacity to impact access, coverage, and reimbursement for your portfolio. Whether you are bringing your first product to market or entering a new therapeutic area, our team will leverage our deep relationships with influencers to identify the key decision-makers you need to engage to ensure future success.

Validate the appeal and relevance of potential positioning platforms for your product among oncology/hematology providers, in consideration of unmet needs, differentiation, and key benefits.

Innovation Partners drives your commercial success and value proposition strategy through in-depth qualitative and quantitative market research, one-on-one interviews, advisory boards, as well as literature review, HEOR studies, and clinical trial data. Innovation Partners supports your product development strategy and provides the insights needed to design the robust value story to meet the needs of your future clients. Through primary and secondary research and advisory boards, you will reach stakeholders across the oncology ecosystem to determine the best strategy to position your product and showcase unmet need.

Using qualitative/quantitative methods to determine which concept(s) will align with the positioning and gain marketplace attention.

Test discrete messaging as it appears in specific marketing materials, specifically in consideration of MOA, Efficacy, Safety, and other key attributes of your product. Provide recommendations to refine and optimize the materials in consideration of your Corporate goals and objectives.

Launch Solutions

Using quantitative survey methodologies, Innovation Partners will evaluate the efficiency and effectiveness of your virtual and in-person field-based engagements. IP’s dedicated market research experts will work with you to develop key questions, identify and survey respondents, and provide real-time feedback through quantitative benchmarking and analysis. With access to thousands of providers, our team will deploy surveys to your preferred network, whether it be 10 or 100 contacts, and provide rapid results. Quarterly reports will provide geographic breakdowns designed to highlight national and regional trends and address any barriers to access.

The TPP which communicates potential scenarios (best-worst case efficacy, AEs) or actual as seen in later clinical trial results informs many of the decisions and tactics that are needed by commercial teams: These include Early Phase Research with potential TPP scenarios can also be used n early phases to inform the strategy for pipeline innovations and assess those with more favorable forecasts. Business Development/Licensing of external assets where the TPP is used to assess interest in the product, potential use and an early estimate of market size. PreLaunch activities to help the Commercial team refine their and strategic plan for the product.

In order to optimize your KOL Identification and Outreach plan, our team will develop a map of potential influencers across Academic Hospitals and Large Community Oncology Practices with the potential to act as champions for your product in support of increased access for patients through a quantitative peer-nomination process.

As a first step, our expert team will conduct secondary research to understand provider reach, including completion of a medical literature review to identify influential publishers and a review of CME events/major conferences to identify influential speakers/presenters with expertise and influence in disease and who have the capacity to impact access, coverage, and reimbursement for the product in support of increased access for patients through a quantitative peer-nomination process.

Following the secondary research, identified HCPs will be validated through primary market research quantitative interviews to execute the peer-nomination process to identify key influencers and opinion leaders in the disease, specifically as it relates to access for your product.

Access to KOLs and other key stakeholders for meetings and research, assess your competitors’ booths/attendance; attend competitor presentations to understand their positioning vs. your product.

IP will conduct primary market research aimed at understanding the level of market awareness, source of awareness, familiarity, and perceptions of your company vs. key competitors and product vs. key competitors. Baseline assessments are conducted in advance of FDA approval in order to allow for the tracking of trends over time and market performance updates will allow your company to see the impact of your commercialization efforts. ATU research will also aim to understand the awareness and recall of your product’s clinical research findings, how clinicians react to them and why; how clinicians learn of about your product’s clinical findings, opportunities and barriers for your product, and the level of competitor activity in the market (e.g.; sales rep calls, MSLs).

Voice of the customer research will inform what messages stakeholders are retaining and how they are informing and impacting consideration of your product.

Often packaging/labeling/IFU are not vetted for use by the target stakeholders and become a problem to solve. Ensuring that stakeholders are able to efficiently and accurately use the product proactively informs the final materials.

Your materials shouldn’t raise more questions than answers. Conduct research with stakeholders to ensure the time, effort and budget investments are yielding materials that will inform and educate clearly and effectively.

Voice of the customer research will inform what messages stakeholders are retaining and how they are informing and impacting consideration of your product.

Business Development Due Diligence

As you look to license or acquire new assets, having a trusted partner to provide reliable information and guide you in your decisions is essential. Innovation Partners has the experience and expertise to analyze market potential, develop sales forecasting and price sensitivity analyses, and present a comprehensive outlook on the market access landscape in order to support recommendations for your business development teams. Our relationships with experts across oncology, hematology, and rare disease combined with our team’s experience working within early stage, mid-size, and multi-national manufacturers can give you the peace of mind to ensure your decisions are well-informed, setting you up for long-term success.

The TPP which communicates potential scenarios (best-worst case efficacy, AEs) or actual as seen in later clinical trial results informs many of the decisions and tactics that are needed by commercial teams: These include Early Phase Research with potential TPP scenarios can also be used n early phases to inform the strategy for pipeline innovations and assess those with more favorable forecasts. Business Development/Licensing of external assets where the TPP is used to assess interest in the product, potential use and an early estimate of market size. PreLaunch activities to help the Commercial team refine their and strategic plan for the product.

Roster & Brand Experience

To see our client roster and brand experience contact us for a copy of our capabilities presentation.

Go to Top